Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study

Olivia Lacroix, Alexandra Couttenier, Evelien Vaes, Chris R Cardwell, Harlinde De Schutter, Annie Robert

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE: Preclinical studies have shown that statins reduce proliferation in esophageal cancer. Three recent observational studies have shown encouraging results but suffered from limitations. This work aimed to assess at the Belgian population level whether statin usage was associated with a decreased mortality in esophageal cancer patients.

METHODS: We conducted an observational, population-based study by linking data of the Belgian Cancer Registry (BCR) with medical claims data coming from health insurance companies and mortality records collected by regional governments for patients diagnosed with esophageal cancer between 2004 and 2014. Using time-dependent Cox regression models, hazard ratios (HRs) and 95% confidence intervals (CI) for overall and cancer-specific mortality were calculated.

RESULTS: Of 6,238 patients with stage I-III esophageal cancer, post-diagnostic use of statins was found in 1,628 (26%) patients. Statins use after diagnosis was associated with a reduction in overall mortality (adjusted HR = 0.84, 95% CI [0.77; 0.92]) and cancer-specific mortality (adjusted HR = 0.87, 95% CI [0.78; 0.97]). Similar association were also seen for pre-diagnostic statin use in overall (adjusted HR = 0.83, 95% CI [0.76-0.91]) and cancer-specific analysis (adjusted HR = 0.86, 95% CI [0.77-0.96]).

CONCLUSIONS: In this large cohort of Belgian patients with esophageal cancer, statins use after diagnosis was associated with a decreased mortality.

LanguageEnglish
Pages385-393
Number of pages9
JournalCancer Causes & Control: an international journal of studies of cancer in human populations
Volume30
Issue number4
Early online date28 Feb 2019
DOIs
Publication statusPublished - 01 Apr 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Esophageal Neoplasms
Survival
Confidence Intervals
Mortality
Population
Neoplasms
Health Insurance
Proportional Hazards Models
Observational Studies
Registries

Cite this

@article{82980a1ce26d48a59d3d7792b991ad2b,
title = "Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study",
abstract = "PURPOSE: Preclinical studies have shown that statins reduce proliferation in esophageal cancer. Three recent observational studies have shown encouraging results but suffered from limitations. This work aimed to assess at the Belgian population level whether statin usage was associated with a decreased mortality in esophageal cancer patients.METHODS: We conducted an observational, population-based study by linking data of the Belgian Cancer Registry (BCR) with medical claims data coming from health insurance companies and mortality records collected by regional governments for patients diagnosed with esophageal cancer between 2004 and 2014. Using time-dependent Cox regression models, hazard ratios (HRs) and 95{\%} confidence intervals (CI) for overall and cancer-specific mortality were calculated.RESULTS: Of 6,238 patients with stage I-III esophageal cancer, post-diagnostic use of statins was found in 1,628 (26{\%}) patients. Statins use after diagnosis was associated with a reduction in overall mortality (adjusted HR = 0.84, 95{\%} CI [0.77; 0.92]) and cancer-specific mortality (adjusted HR = 0.87, 95{\%} CI [0.78; 0.97]). Similar association were also seen for pre-diagnostic statin use in overall (adjusted HR = 0.83, 95{\%} CI [0.76-0.91]) and cancer-specific analysis (adjusted HR = 0.86, 95{\%} CI [0.77-0.96]).CONCLUSIONS: In this large cohort of Belgian patients with esophageal cancer, statins use after diagnosis was associated with a decreased mortality.",
author = "Olivia Lacroix and Alexandra Couttenier and Evelien Vaes and Cardwell, {Chris R} and {De Schutter}, Harlinde and Annie Robert",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s10552-019-01149-3",
language = "English",
volume = "30",
pages = "385--393",
journal = "Cancer Causes & Control: an international journal of studies of cancer in human populations",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "4",

}

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. / Lacroix, Olivia; Couttenier, Alexandra; Vaes, Evelien; Cardwell, Chris R; De Schutter, Harlinde; Robert, Annie.

In: Cancer Causes & Control: an international journal of studies of cancer in human populations, Vol. 30, No. 4, 01.04.2019, p. 385-393.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study

AU - Lacroix, Olivia

AU - Couttenier, Alexandra

AU - Vaes, Evelien

AU - Cardwell, Chris R

AU - De Schutter, Harlinde

AU - Robert, Annie

PY - 2019/4/1

Y1 - 2019/4/1

N2 - PURPOSE: Preclinical studies have shown that statins reduce proliferation in esophageal cancer. Three recent observational studies have shown encouraging results but suffered from limitations. This work aimed to assess at the Belgian population level whether statin usage was associated with a decreased mortality in esophageal cancer patients.METHODS: We conducted an observational, population-based study by linking data of the Belgian Cancer Registry (BCR) with medical claims data coming from health insurance companies and mortality records collected by regional governments for patients diagnosed with esophageal cancer between 2004 and 2014. Using time-dependent Cox regression models, hazard ratios (HRs) and 95% confidence intervals (CI) for overall and cancer-specific mortality were calculated.RESULTS: Of 6,238 patients with stage I-III esophageal cancer, post-diagnostic use of statins was found in 1,628 (26%) patients. Statins use after diagnosis was associated with a reduction in overall mortality (adjusted HR = 0.84, 95% CI [0.77; 0.92]) and cancer-specific mortality (adjusted HR = 0.87, 95% CI [0.78; 0.97]). Similar association were also seen for pre-diagnostic statin use in overall (adjusted HR = 0.83, 95% CI [0.76-0.91]) and cancer-specific analysis (adjusted HR = 0.86, 95% CI [0.77-0.96]).CONCLUSIONS: In this large cohort of Belgian patients with esophageal cancer, statins use after diagnosis was associated with a decreased mortality.

AB - PURPOSE: Preclinical studies have shown that statins reduce proliferation in esophageal cancer. Three recent observational studies have shown encouraging results but suffered from limitations. This work aimed to assess at the Belgian population level whether statin usage was associated with a decreased mortality in esophageal cancer patients.METHODS: We conducted an observational, population-based study by linking data of the Belgian Cancer Registry (BCR) with medical claims data coming from health insurance companies and mortality records collected by regional governments for patients diagnosed with esophageal cancer between 2004 and 2014. Using time-dependent Cox regression models, hazard ratios (HRs) and 95% confidence intervals (CI) for overall and cancer-specific mortality were calculated.RESULTS: Of 6,238 patients with stage I-III esophageal cancer, post-diagnostic use of statins was found in 1,628 (26%) patients. Statins use after diagnosis was associated with a reduction in overall mortality (adjusted HR = 0.84, 95% CI [0.77; 0.92]) and cancer-specific mortality (adjusted HR = 0.87, 95% CI [0.78; 0.97]). Similar association were also seen for pre-diagnostic statin use in overall (adjusted HR = 0.83, 95% CI [0.76-0.91]) and cancer-specific analysis (adjusted HR = 0.86, 95% CI [0.77-0.96]).CONCLUSIONS: In this large cohort of Belgian patients with esophageal cancer, statins use after diagnosis was associated with a decreased mortality.

U2 - 10.1007/s10552-019-01149-3

DO - 10.1007/s10552-019-01149-3

M3 - Article

VL - 30

SP - 385

EP - 393

JO - Cancer Causes & Control: an international journal of studies of cancer in human populations

T2 - Cancer Causes & Control: an international journal of studies of cancer in human populations

JF - Cancer Causes & Control: an international journal of studies of cancer in human populations

SN - 0957-5243

IS - 4

ER -